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The above-mentioned article indicates in the legend to Figure 1 that residuals were computed from regressing each of the
variables on age, sex, diabetes duration, A1c, ACR, mGFR, body mass index, and mean arterial pressure. As noted in the
Methods and in the Results, we adjusted for each of these covariates except for ACR and mGFR when creating these
ﬁgures. In the ﬁgure itself the 2 left panels now correctly illustrate the relationships between ECF and TNFR1 and TNFR2.
Below is the correct version of Figure 1 and its legend.0
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Figure 1 | Partial regression residual plot of the associations between TNFRs, percentage of normal endothelial cell fenestration (ECF),
and mesangial fractional volume (VvMes). The residuals were computed from regressing each of these variables on age, sex, diabetes
duration, A1c, body mass index, and mean arterial pressure. Exclusion of the single outlier did not change the signiﬁcance of the associations
with the 2 morphometric variables. A1c, hemoglobin A1c; TNFR, tumor necrosis factor receptor.Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective treatment in pediatric patients
with atypical hemolytic uremic syndrome. Kidney Int. 2016;89:701–711OPEN
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